|
1
|
Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.
|
Cancer Res
|
2010
|
2.77
|
|
2
|
Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.
|
J Natl Cancer Inst
|
2007
|
2.75
|
|
3
|
Mammary stem cells and breast cancer--role of Notch signalling.
|
Stem Cell Rev
|
2007
|
2.62
|
|
4
|
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
|
Clin Cancer Res
|
2012
|
2.24
|
|
5
|
A detailed mammosphere assay protocol for the quantification of breast stem cell activity.
|
J Mammary Gland Biol Neoplasia
|
2012
|
1.98
|
|
6
|
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
|
Breast Cancer Res
|
2013
|
1.92
|
|
7
|
The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer.
|
Cancer Res
|
2004
|
1.72
|
|
8
|
The mammary gland "side population": a putative stem/progenitor cell marker?
|
J Mammary Gland Biol Neoplasia
|
2005
|
1.57
|
|
9
|
Steroid receptors and cell cycle in normal mammary epithelium.
|
J Mammary Gland Biol Neoplasia
|
2004
|
1.47
|
|
10
|
The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis.
|
BMC Med Genomics
|
2008
|
1.41
|
|
11
|
Origins of breast cancer subtypes and therapeutic implications.
|
Nat Clin Pract Oncol
|
2007
|
1.36
|
|
12
|
Wnt pathway activity in breast cancer sub-types and stem-like cells.
|
PLoS One
|
2013
|
1.21
|
|
13
|
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
|
Breast Cancer Res Treat
|
2010
|
1.18
|
|
14
|
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.
|
Breast Cancer Res
|
2013
|
1.16
|
|
15
|
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.
|
Breast Cancer Res
|
2008
|
1.14
|
|
16
|
Risk determination and prevention of breast cancer.
|
Breast Cancer Res
|
2014
|
1.11
|
|
17
|
Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.
|
Breast Cancer Res
|
2009
|
1.10
|
|
18
|
The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers.
|
Mol Cell Biol
|
2010
|
1.10
|
|
19
|
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.
|
Breast Cancer Res
|
2006
|
1.09
|
|
20
|
Breast cancer stem cells: something out of notching?
|
Cancer Res
|
2010
|
1.05
|
|
21
|
Resistance to endocrine therapy: are breast cancer stem cells the culprits?
|
J Mammary Gland Biol Neoplasia
|
2009
|
1.02
|
|
22
|
Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling.
|
Breast Cancer Res
|
2013
|
1.02
|
|
23
|
A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.
|
Oncotarget
|
2014
|
1.00
|
|
24
|
Disruption of a Quorum Sensing mechanism triggers tumorigenesis: a simple discrete model corroborated by experiments in mammary cancer stem cells.
|
Biol Direct
|
2010
|
1.00
|
|
25
|
Stem cells in breast tumours: are they ready for the clinic?
|
Eur J Cancer
|
2012
|
1.00
|
|
26
|
Human breast epithelial stem cells and their regulation.
|
J Pathol
|
2006
|
1.00
|
|
27
|
P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer.
|
Stem Cells
|
2012
|
0.99
|
|
28
|
High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?
|
Breast Cancer Res
|
2006
|
0.98
|
|
29
|
Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity.
|
Oncotarget
|
2013
|
0.97
|
|
30
|
Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status.
|
Cancer Res
|
2012
|
0.96
|
|
31
|
Biomarkers of dietary energy restriction in women at increased risk of breast cancer.
|
Cancer Prev Res (Phila)
|
2009
|
0.96
|
|
32
|
Breast cancer stem cells and their role in resistance to endocrine therapy.
|
Horm Cancer
|
2011
|
0.95
|
|
33
|
Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
|
Clin Cancer Res
|
2013
|
0.90
|
|
34
|
Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity.
|
Cell Cycle
|
2013
|
0.89
|
|
35
|
P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells.
|
Oncotarget
|
2014
|
0.87
|
|
36
|
It's all in the details: methods in breast development and cancer.
|
Breast Cancer Res
|
2009
|
0.87
|
|
37
|
Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.
|
PLoS One
|
2013
|
0.85
|
|
38
|
Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy.
|
Stem Cells
|
2015
|
0.84
|
|
39
|
Dickkopf1 regulates fate decision and drives breast cancer stem cells to differentiation: an experimentally supported mathematical model.
|
PLoS One
|
2011
|
0.83
|
|
40
|
Are stem-like cells responsible for resistance to therapy in breast cancer?
|
Breast Dis
|
2008
|
0.82
|
|
41
|
Targeting IL-8 signalling to inhibit breast cancer stem cell activity.
|
Expert Opin Ther Targets
|
2013
|
0.82
|
|
42
|
Combining Notch inhibition with current therapies for breast cancer treatment.
|
Ther Adv Med Oncol
|
2013
|
0.81
|
|
43
|
Mechanisms of Disease: prediction and prevention of breast cancer--cellular and molecular interactions.
|
Nat Clin Pract Oncol
|
2005
|
0.79
|
|
44
|
Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells.
|
Nanotechnology
|
2016
|
0.78
|
|
45
|
Normal breast tissue implanted into athymic nude mice identifies biomarkers of the effects of human pregnancy levels of estrogen.
|
Cancer Prev Res (Phila)
|
2009
|
0.78
|
|
46
|
Lack of caveolin-1 (P132L) somatic mutations in breast cancer.
|
Breast Cancer Res Treat
|
2012
|
0.78
|
|
47
|
17β-estradiol regulates giant vesicle formation via estrogen receptor-alpha in human breast cancer cells.
|
Oncotarget
|
2014
|
0.77
|
|
48
|
‘The charmingest place’: non-coding RNA, lineage tracing, tumor heterogeneity, metastasis and metabolism--new methods in mammary gland development and cancer: the fifth ENBDC Workshop.
|
Breast Cancer Res
|
2013
|
0.75
|
|
49
|
The devil is in the methods: lineage tracing, functional screens and sequencing, hormones, tumour-stroma interactions, and expansion of human breast tumours as xenografts.
|
Breast Cancer Res
|
2011
|
0.75
|
|
50
|
Estrogen deprivation for breast cancer prevention.
|
Recent Results Cancer Res
|
2007
|
0.75
|
|
51
|
Interrogating open issues in cancer medicine with patient-derived xenografts.
|
Nat Rev Cancer
|
2017
|
0.75
|